To advance clinical development of docirbrutinib and monzosertib, Carna Biosciences, Inc. will carry out a 561 million yen convertible bond with warrants issuance and an 850 million yen equity issuance. Proceeds will be allocated to clinical development, preclinical work, and working capital, and the structure spreads dilution.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Carna Biosciences, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4572-20260928-02.pdf","jir_short_summary":"To advance clinical development of docirbrutinib and monzosertib, Carna Biosciences, Inc. will carry out a 561 million yen convertible bond with warrants issuance and an 850 million yen equity issuance. Proceeds will be allocated to clinical development, preclinical work, and working capital, and the structure spreads dilution.","jir_summary":"### Overview of Fundraising\nCarna Biosciences, Inc. is conducting this fundraising to reliably advance the clinical development of docirbrutinib (AS-1763) and monzosertib (AS-0141), enhance pipeline value, and maintain funding levels. By combining a convertible bond with warrants issuance and an equity issuance, the company secures a substantial amount of funds while dispersing dilution.\n\n### Use of Proceeds and Breakdown of Fundraising\nProceeds will be used for clinical development costs for docirbrutinib and monzosertib, preclinical pipeline development costs, and working capital. Through allocations for the 4th to 6th tranches, a total of approximately 1,369 million yen is planned to be raised. Allottees include Cantor Fitzgerald Europe and others.","jir_financial_highlights":"Proceeds from convertible bond with warrants issuance program: 561 million yen (Unknown)\nProceeds from equity issuance: 850 million yen (Unknown)\nIssuance costs (deduction): -42 million yen (Unknown)","jir_category":"","jir_hashtags":"#CarnaBiosciences, #CapitalPolicy, #Fundraising, #ConvertibleBondWithWarrants, #PublicOffering","jir_key_figures":"Convertible bond with warrants issuance proceeds: 561 million yen\nEquity issuance proceeds: 850 million yen\nIssuance costs (deduction): -42 million yen","jir_meta_title":"Carna Biosciences, Inc. \u2014 Supplementary Fundraising Explanation\uff5cSeptember 2026","jir_meta_description":"Carna Biosciences, Inc. announced fundraising to cover clinical development and related costs. Through a convertible bond with warrants issuance and equity issuance, approximately 1,369 million yen in total will be secured, with allottees and uses disclosed.","jir_og_title":"Carna Biosciences, Inc. Supplementary Fundraising Explanation\uff5cSeptember 2026","jir_og_description":"Securing funds via convertible bond with warrants issuance and equity issuance. Explains use of proceeds for clinical development and measures to mitigate dilution.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-123865","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n